Correction: choroid plexus carcinoma.
|Article Type:||Letter to the editor|
|Publication:||Name: Archives of Pathology & Laboratory Medicine Publisher: College of American Pathologists Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 College of American Pathologists ISSN: 1543-2165|
|Issue:||Date: May, 2009 Source Volume: 133 Source Issue: 5|
To the Editor.--It was brought to our attention that there is an
error in the table of our recently published Resident Short Review
article in the August 2008 issue of the Archives (Gopal P, Parker JR,
Debski R, Parker JC Jr. Choroid plexus carcinoma. Arch Pathol Lab Med.
2008;132:13501354). The table states that atypical teratoid/rhabdoid
tumor is negative for epithelial membrane antigen (EMA); however, this
is incorrect in that most of these tumors stain with EMA. In addition,
we have decided to modify the staining characteristics for CAM 5.2 and
glial fibrillary acidic protein in papillary meningioma from negative to
not applicable be cause these characteristics are not fully understood
in papillary meningioma, specifically.
We also clarified the original table footnote to facilitate better understanding by readers. We apologize for any confusion. The revised table below reflects all of these changes.
The author has no relevant financial interest in the products or companies described in this article.
PURVA GOPAL, MD
Department of Pathology
university of Louisville
Louisville, KY 40292
Table. Immunohistochemical Staining of Tumors in Differential Diagnosis of Choroid Plexus Carcinoma (CPC) (a) Trans- CAM 5.2 thyretin GFAP EMA INI1 CPC + +/- +/- - + Papillary ependymoma - NA + +/- + Papillary meningioma NA NA NA + NA Atypical teratoid/ rhabdoid tumor +/- NA + + - Stannio- Kir 7.1 calcin 1 CPC + + Papillary ependymoma - - Papillary meningioma NA NA Atypical teratoid/ rhabdoid tumor - - Abbreviations: EMA, epithelial membrane antigen; GFAP, glial fibrillary acidic protein; INI1, integrase interactor 1; NA, not applicable; +, >50% of tumors stain; +/-, 15% to 49% of tumors stain; -, <15% of tumors stain.
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|